OpenVSafe by OpenVAERS
Search V-safe

983-20970-92954

3 vaccinations 5 coded responses 8 check-ins 5 free-text entries 3 call cases
Sex
Female
Age at first dose
36-40
ZIP prefix
852 / AZ
Registered
2021-02-26
Relationship
Self
Race
White
Ethnicity
Not Hispanic or Latino

Timeline

  1. 2020-12-27
    Dose 1 — Pfizer-BioNTech
  2. 2021-01-20
    Dose 2 — Pfizer-BioNTech
  3. 2021-02-26
    Registered in v-safe
  4. 2021-02-26
    Health check-in — day 35, dose 2
    Feeling: Good
    Adult check-in
  5. 2021-03-03
    Health check-in — day 42, dose 2
    Feeling: Good
    Adult check-in
  6. 2021-04-21
    Health check-in — 3 months, dose 2
    Feeling: Good
    Adult check-in
  7. 2021-07-21
    Survey response — 6 months, dose 2
    MedDRA: Migraine, Self-medication — Feeling: Fair · Be unable to do your normal daily activities
    Free text: Break through migraine yesterday (7/20), treated with my usual medication.
    MedDRA releases: 2024-11 · check-in free text available
  8. 2021-11-29
    Dose 3 — Pfizer-BioNTech
  9. 2022-01-20
    Survey response — 12 months, dose 2
    MedDRA: Hypertension, Office visit — Feeling: Fair · Get care from a doctor or other healthcare professional
    Free text: Symptoms: Hypertension · Healthcare visit (other): In person pcp visit
    MedDRA releases: 2024-11 · check-in free text available
  10. 2022-01-20
    Report sent to call center — 12 months, dose 2
    Get care from a doctor or other healthcare professional
    1 call case(s)
  11. 2022-01-21
  12. 2022-02-28
    Survey response — 3 months, dose 3
    MedDRA: Haemorrhagic ovarian cyst, Hypertension, Immune system disorder, Office visit — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visit
    Free text: Symptoms: Hemorrhagic ovarian cyst, new onset hypertension, moderate immune reaction to the booster · Healthcare visit (other): Discovered htn at routine pcp visit
    MedDRA releases: 2024-11 · check-in free text available
  13. 2022-02-28
    Report sent to call center — 3 months, dose 3
    Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare pr
    Outpatient clinic or urgent care clinic visit · 1 call case(s)
  14. 2022-03-17
  15. 2022-05-30
    Survey response — 6 months, dose 3
    MedDRA: Adenomyosis, Adhesiolysis, Endometriosis, Hysterectomy, Pre-existing disease, Salpingo-oophorectomy unilateral, Surgery — Feeling: Fair · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visit, Hospitalization
    Free text: Symptoms: Poorly controled prior htn. New: Endometrioma requiring total hysterectomy with left salpingoophorectomy and lysis of extensive adhesions. Dx w/ silent extensive endomeriosis, pathology also showed asymptomatic adenomyosis · Healthcare visit (other): Surgery
    MedDRA releases: 2024-11 · check-in free text available
  16. 2022-05-30
    Report sent to call center — 6 months, dose 3
    Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare pr
    Outpatient clinic or urgent care clinic visit · Hospitalization · 1 call case(s)
  17. 2022-06-01
    Call successful
    Not applicable – Participant does not believe symptoms are related to vaccine and does not wish to fill
  18. 2022-06-01
    Call successful
    Not applicable – Participant does not believe symptoms are related to vaccine and does not wish to fill
  19. 2022-06-01
    Call successful
    Not applicable – Participant does not believe symptoms are related to vaccine and does not wish to fill
  20. 2022-12-01
    Survey response — 12 months, dose 3
    MedDRA: Glucose tolerance impaired, Glycosylated haemoglobin increased — Feeling: Good
    Free text: Increased A1C, pre-diabetic
    MedDRA releases: 2024-11 · check-in free text available

Vaccinations

DoseDateManufacturerCo-administered
12020-12-27Pfizer-BioNTech
22021-01-20Pfizer-BioNTech
32021-11-29Pfizer-BioNTech No

Call center

3 call center cases

3 successful

See the call center timeline

Free text

Release 9 — 6 months, dose 2

2021-07-21

Symptoms: Break through migraine yesterday (7/20), treated with my usual medication.

Release 10 — 12 months, dose 2

2022-01-20

Symptoms: Hypertension
Healthcare visit (other): In person pcp visit

Release 11 — 3 months, dose 3

2022-02-28

Symptoms: Hemorrhagic ovarian cyst, new onset hypertension, moderate immune reaction to the booster
Healthcare visit (other): Discovered htn at routine pcp visit

Release 11 — 6 months, dose 3

2022-05-30

Symptoms: Poorly controled prior htn. New: Endometrioma requiring total hysterectomy with left salpingoophorectomy and lysis of extensive adhesions. Dx w/ silent extensive endomeriosis, pathology also showed asymptomatic adenomyosis
Healthcare visit (other): Surgery

Release 12 — 12 months, dose 3

2022-12-01

Symptoms: Increased A1C, pre-diabetic

Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".

MedDRA terms by release

FieldPreferred term2021-092023-042024-11
HCVOHypertension · · ✓
HCVOOffice visit · · ✓
HCVOSurgery · · ✓
SDAdenomyosis · · ✓
SDAdhesiolysis · · ✓
SDEndometriosis · · ✓
SDGlucose tolerance impaired · · ✓
SDGlycosylated haemoglobin increased · · ✓
SDHaemorrhagic ovarian cyst · · ✓
SDHypertension · · ✓
SDHysterectomy · · ✓
SDImmune system disorder · · ✓
SDMigraine · · ✓
SDPre-existing disease · · ✓
SDSalpingo-oophorectomy unilateral · · ✓
SDSelf-medication · · ✓

✓ active code · ○ coded but marked inactive · blank = not in that release